The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
This study has been completed.
Sponsor:
Jonsson Comprehensive Cancer Center
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT01180868
First received: August 11, 2010
Last updated: July 27, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the biodistribution of a new agent 1-L-(2 deoxy-2,-18fluoroarabinofuranosyl) cytosine non-invasively in healthy humans and to evaluate whether it can be used to image cancer, autoimmune disease, and inflammation
| Condition |
|---|
|
Autoimmune Diseases Cancer |
| Study Type: | Observational |
| Official Title: | The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases |
Resource links provided by NLM:
Further study details as provided by Jonsson Comprehensive Cancer Center:
| Enrollment: | 1 |
| Study Start Date: | May 2008 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
patients with cancer
patients with hematological malignancies and solid tumors
|
|
patients with autoimmune dosorders
patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
|
| healthy subjects |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Patients with cancer, patients with autoimmune dosorders, and healthy subjects.
Criteria
Inclusion Criteria:
- greater than 18 years of age
- women of childbearing potential will undergo a pregnancy test free of charge
- patients with hematological malignancies, solid tumors or autoimmune disorders
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01180868
Please refer to this study by its ClinicalTrials.gov identifier: NCT01180868
Locations
| United States, California | |
| UCLA | |
| Los Angeles, California, United States, 90095 | |
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
| Principal Investigator: | Christiaan Schiepers, M.D. Ph.D | University of California, Los Angeles |
More Information
| Responsible Party: | Jonsson Comprehensive Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01180868 History of Changes |
| Other Study ID Numbers: |
08-02-049 DE-PS02-08ER08-01 ( Other Grant/Funding Number: Department of Energy ) CIRM No. RT1-01126-1 ( Other Grant/Funding Number: California Institute for Regenerative Medicine ) |
| Study First Received: | August 11, 2010 |
| Last Updated: | July 27, 2012 |
Keywords provided by Jonsson Comprehensive Cancer Center:
|
imaging probe cancer inflammatory tissue inflammatory diseases |
Additional relevant MeSH terms:
|
Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 25, 2017